Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

Dishman Carbogen Amcis subsidiary, Carbogen Amcis, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.

The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:

- Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.

- Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.

"This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers," said Stephan Fritschi, CEO at CARBOGEN AMCIS. "We're proud to continue building on our strong trust and technical collaboration foundation."

Carbogen Amcis is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company's infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.

"By investing in both Aarau and Neuland, we're ensuring that our infrastructure keeps pace with our customers' ambitions," said Carl Baker, Vice President Business Unit Drug Substance. "These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies."

With facilities across Switzerland, France, the UK, the Netherlands, and China, Carbogen Amcis continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.